Cargando…

MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion

BACKGROUND: MiR-221/-222 are frequently overexpressed in breast cancer and are associated with increased malignancy. The specific modification of microRNAs (miRNAs) expression could be a promising strategy in breast cancer therapy, leading to the suppression of tumourigenic processes in tumour cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Falkenberg, N, Anastasov, N, Rappl, K, Braselmann, H, Auer, G, Walch, A, Huber, M, Höfig, I, Schmitt, M, Höfler, H, Atkinson, M J, Aubele, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833215/
https://www.ncbi.nlm.nih.gov/pubmed/24129242
http://dx.doi.org/10.1038/bjc.2013.625
_version_ 1782291808745684992
author Falkenberg, N
Anastasov, N
Rappl, K
Braselmann, H
Auer, G
Walch, A
Huber, M
Höfig, I
Schmitt, M
Höfler, H
Atkinson, M J
Aubele, M
author_facet Falkenberg, N
Anastasov, N
Rappl, K
Braselmann, H
Auer, G
Walch, A
Huber, M
Höfig, I
Schmitt, M
Höfler, H
Atkinson, M J
Aubele, M
author_sort Falkenberg, N
collection PubMed
description BACKGROUND: MiR-221/-222 are frequently overexpressed in breast cancer and are associated with increased malignancy. The specific modification of microRNAs (miRNAs) expression could be a promising strategy in breast cancer therapy, leading to the suppression of tumourigenic processes in tumour cells. METHODS: MiR-221/-222 expressions were analysed in 86 breast cancer tissues by quantitative RT–PCR and tested for correlation with immunohistochemistry data and clinical follow-up. In vitro assays were conducted using human breast cancer cell lines with lentiviral overexpression of miR-221/-222. RESULTS: In tumour tissues, miR-221/-222 were associated with the occurrence of distant metastases. In particular, high levels of miR-221 were revealed to have a high prognostic impact for the identification of significantly different groups with advanced tumours. MiR-221/-222 overexpression strongly increased cell proliferation and invasion in vitro. Following miR-221/-222 overexpression an increased uPAR expression and cell invasion were observed. CONCLUSION: This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy.
format Online
Article
Text
id pubmed-3833215
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38332152014-11-12 MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion Falkenberg, N Anastasov, N Rappl, K Braselmann, H Auer, G Walch, A Huber, M Höfig, I Schmitt, M Höfler, H Atkinson, M J Aubele, M Br J Cancer Molecular Diagnostics BACKGROUND: MiR-221/-222 are frequently overexpressed in breast cancer and are associated with increased malignancy. The specific modification of microRNAs (miRNAs) expression could be a promising strategy in breast cancer therapy, leading to the suppression of tumourigenic processes in tumour cells. METHODS: MiR-221/-222 expressions were analysed in 86 breast cancer tissues by quantitative RT–PCR and tested for correlation with immunohistochemistry data and clinical follow-up. In vitro assays were conducted using human breast cancer cell lines with lentiviral overexpression of miR-221/-222. RESULTS: In tumour tissues, miR-221/-222 were associated with the occurrence of distant metastases. In particular, high levels of miR-221 were revealed to have a high prognostic impact for the identification of significantly different groups with advanced tumours. MiR-221/-222 overexpression strongly increased cell proliferation and invasion in vitro. Following miR-221/-222 overexpression an increased uPAR expression and cell invasion were observed. CONCLUSION: This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy. Nature Publishing Group 2013-11-12 2013-10-15 /pmc/articles/PMC3833215/ /pubmed/24129242 http://dx.doi.org/10.1038/bjc.2013.625 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Falkenberg, N
Anastasov, N
Rappl, K
Braselmann, H
Auer, G
Walch, A
Huber, M
Höfig, I
Schmitt, M
Höfler, H
Atkinson, M J
Aubele, M
MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion
title MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion
title_full MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion
title_fullStr MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion
title_full_unstemmed MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion
title_short MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion
title_sort mir-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833215/
https://www.ncbi.nlm.nih.gov/pubmed/24129242
http://dx.doi.org/10.1038/bjc.2013.625
work_keys_str_mv AT falkenbergn mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT anastasovn mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT rapplk mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT braselmannh mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT auerg mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT walcha mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT huberm mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT hofigi mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT schmittm mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT hoflerh mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT atkinsonmj mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion
AT aubelem mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion